| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 9, 2004
From the Department of Internal Medicine (H.J.M., E.R., J.G., M.S.E.), School of Medicine, University of Ioannina, Ioannina, Greece; the Laboratory of Biochemistry (K.S.), University Hospital of Ioannina, Ioannina, Greece; and the Department of Clinical Biochemistry (D.P.M.), Royal Free Hospital, London, UK. * To whom correspondence should be addressed. E-mail: hmilioni{at}cc.uoi.gr.
Background and Purpose--Metabolic syndrome (MetSyn) represents a constellation of lipid and nonlipid risk factors for cardiovascular disease and is a recognized target for increased behavioral therapy. Objective--The association between acute ischemic/nonembolic stroke and the MetSyn in elderly individuals was assessed in a population-based case-control study in the prefecture of Ioannina, Greece. Study Population--A total of 163 patients aged older than 70 years admitted with first-ever-in-a-lifetime acute ischemic/nonembolic stroke and 166 controls were included. Results--The prevalence of MetSyn (defined according to NCEP/ATP III criteria) was high in stroke patients (46.0% versus 15.7%, P<0.001). Compared with controls as a group (with and without MetSyn), stroke patients with the MetSyn showed higher concentrations of triglycerides, lipoprotein(a), uric acid, and fibrinogen, and lower high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I levels. In logistic regression analysis, crude and adjusted odd ratios (ORs) for MetSyn were 5.33 (95% confidence interval [CI], 2.91 to 9.79; P<0.0001) and 2.59 (95% CI, 1.24 to 5.42; P=0.012), respectively. The analysis of interaction between MetSyn and its individual components revealed significant associations with abdominal obesity (adjusted OR, 2.74; 95% CI, 1.15 to 6.50; P=0.02), hypertension (OR, 2.03; 95% CI, 0.91 to 4.49; P=0.08), high fasting glucose levels (OR, 2.95; 95% CI, 1.19 to 7.35; P=0.02), high triglyceride (OR, 5.55; 95% CI, 2.71 to 11.37; P<0.0001]), and low HDL cholesterol (OR, 5.42; 95% CI, 2.85 to 10.30; P<0.0001). Notably, in stroke patients with the MetSyn the inverse relationship between HDL cholesterol levels and ischemic stroke was negated (OR, 1.04; 95% CI, 1.02 to 1.05; P<0.0001). Conclusions--MetSyn is associated with an increased risk for acute ischemic/nonembolic stroke in elderly subjects with significant contributions from its individual components. In the presence of MetSyn, HDL cholesterol loses its protective role against ischemic stroke.
Revised on March 28, 2005
Accepted on April 8, 2005
Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects
Haralampos J. Milionis MD*;
This article has been cited by other articles:
![]() |
M. Woodward, F. Barzi, V. Feigin, D. Gu, R. Huxley, K. Nakamura, A. Patel, S. Ho, K. Jamrozik, and for the Asia Pacific Cohort Studies Collaboration Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region Eur. Heart J., November 1, 2007; 28(21): 2653 - 2660. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Furie and E. E. Smith Metabolic syndrome: A target for preventing leukoaraiosis and age-related dementia? Neurology, September 4, 2007; 69(10): 951 - 952. [Full Text] [PDF] |
||||
![]() |
K Lipska, P N Sylaja, P S Sarma, K R Thankappan, V R Kutty, R S Vasan, and K Radhakrishnan Risk factors for acute ischaemic stroke in young adults in South India J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 959 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF] |
||||
![]() |
F. Dentali, E. Romualdi, and W. Ageno The metabolic syndrome and the risk of thrombosis Haematologica, March 1, 2007; 92(3): 297 - 299. [Full Text] [PDF] |
||||
![]() |
C. Ay, T. Tengler, R. Vormittag, R. Simanek, W. Dorda, T. Vukovich, and I. Pabinger Venous thromboembolism a manifestation of the metabolic syndrome Haematologica, March 1, 2007; 92(3): 374 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rana, A. C. Jansen, A. H. Zwinderman, M. Nieuwdorp, E. S. van Aalst-Cohen, J. W. Jukema, M. D. Trip, and J. J.P. Kastelein Metabolic Syndrome and Risk of Coronary, Cerebral, and Peripheral Vascular Disease in a Large Dutch Population With Familial Hypercholesterolemia Diabetes Care, May 1, 2006; 29(5): 1125 - 1127. [Full Text] [PDF] |
||||
![]() |
H.-J. Chen, C.-H. Bai, W.-T. Yeh, H.-C. Chiu, and W.-H. Pan Influence of Metabolic Syndrome and General Obesity on the Risk of Ischemic Stroke Stroke, April 1, 2006; 37(4): 1060 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kurl, J. A. Laukkanen, L. Niskanen, D. Laaksonen, J. Sivenius, K. Nyyssonen, and J. T. Salonen Metabolic Syndrome and the Risk of Stroke in Middle-Aged Men Stroke, March 1, 2006; 37(3): 806 - 811. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |